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Abstract Classical randomized controlled trials are the
gold standard in medical evidence because of their high
internal validity. However, their necessarily strict design can
limit their external validity and the ability to extrapolate
these data to real world patients. Therefore, alternatively
designed studies may play a complementary role in
evaluating the comparative effectiveness of therapies in
nonidealized patients in more naturalistic, real world
settings. Observational studies have high external validity
and can evaluate real world outcomes. Their strength lies in
hypothesis generation and testing and in identifying areas in
which further clinical trials may be required. Pragmatic trials
are designed to maximize applicability of trial results to usual
care settings by relying on clinically important outcomes and
enrolling a wide range of participants. A combination of these
approaches is preferable and necessary.
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Clinical Trial Acronyms
ELEVATE A Pragmatic Single-Blind RCT and Health
Economic Evaluation of Leukotriene Receptor
Antagonists in Primary Care at Steps Two and
Three of the National Asthma Guidelines
GOAL Gaining Optimal Asthma Control
IMPACT Investigation of Montelukast as a Partner
Agent for Complementary Therapy
MASCOT Management of Asthma in School-age
Children on Therapy
TORCH Towards a Revolution in COPD Health
UPLIFT Understanding Potential Long-Term Impacts
on Function With Tiotropium
Introduction
Due to their high internal validity, classical randomized
controlled trials (cRCTs) unequivocally sit atop the medical
evidence hierarchy for examining management and thera-
peutic interventions [1–3]. To limit organizational con-
straints, costs, and patient dropouts, many cRCTs are of
short duration, although 1-year cRCTs have been carried
out [4–6]. Of particular importance, they are designed to
include tightly controlled, well-characterized patient pop-
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DOI 10.1007/s11882-011-0222-7ulations so as to minimize confounders and avoid loose
causality relationships between an intervention and an
outcome, seeking instead to identify clear cause and effect.
For example, patients typically recruited to asthma cRCTs
tend to have a clear-cut diagnosis; frequent use of rescue
medication; substantial, concurrent reversibility to short-
acting β2-agonists; high adherence with study drugs and
procedures; good inhaler technique; and no (or negligible)
comorbid illness. The resultant highly characterized trial
population represents but a small subgroup of the broadly
heterogeneous asthma population treated in everyday
clinical practice.
For common chronic conditions (eg, asthma) that affect a
wide, varied patient population, concerns exist regarding
the external validity of cRCT data and the ability to broadly
extrapolate these data to the real world patient population
[7–9, 10￿]. This paper examines the extent to which the
findings of cRCTs in respiratory medicine, particularly with
respect to asthma, can be generalized to the broader
population. In addition, we consider complementary study
designs and the role they play in supplementing the cRCT
evidence base.
Gaps in the Evidence Base
Do Classical Randomized Controlled Trial Asthma
Populations Represent Real Life Patients with Asthma?
Randomized controlled trials (RCTs) can be designed to
show superiority, noninferiority, or equivalence and are
used to evaluate the safety profile and efficacy of emerging
therapies. Classical RCT design aims to maximize internal
validity and to establish an unequivocal cause-and-effect
relationship between an intervention and an outcome, and
only a limited number of outcomes are evaluated. However,
to establish causality, any potential confounding factor that
may compromise results and their interpretation must be
eliminated (as far as is realistically possible).
However, the strict patient selection criteria used in most
cRCTs tend to result in a highly restricted (normally
idealized) study population. The inclusion criteria of
asthma cRCTs generally demand excellent inhaler tech-
nique and compliance with the designated treatment,
prespecified levels of airflow obstruction and reversibility,
absence of comorbidities (including obesity) and polyphar-
macy, and specific smoking status (eg, current nonsmoker
with smoking history of ≤10 pack-years). In contrast,
patients with asthma treated in clinical practice frequently
have comorbidities, variable compliance, and questionable
inhaler technique (Table 1)[ 11–15]. In addition, in the real
world, a significant proportion are current smokers and/or
overweight [16, 17]. The net result is that cRCT study
populations tend to represent only very limited populations
within the real world asthma population [18–20].
Global Initiative for Asthma–Based Asthma Diagnostic
Criteria Used in Classical Randomized Controlled Trials:
Relevance in the Real World
The Global Initiative for Asthma (GINA) publishes
management and therapeutic recommendations that draw
heavily on cRCT evidence [3]. To be included in cRCTs,
patients must fulfill strict GINA-based diagnostic criteria to
ensure that observed effects are not obscured by other
actors (“confounders”) introduced, for example, by inclu-
sion of patients with obstructive lung disease other than
asthma (eg, chronic obstructive pulmonary disease
Table 1 Comorbid and lifestyle factors present in real world patients with asthma who are frequently excluded from classical randomized
controlled trial populations
Comorbid disease/lifestyle factor Prevalence/degree of problem among patients with asthma
Rhinitis and rhinosinusitis 24%–94% (as measured in a range of European and American studies)
50%–100% (lifetime prevalence)
Anxiety and depression 25%–50% (prevalence in severe and difficult-to-control asthma)
Obesity Prevalence has increased concurrently with that of asthma over the past decades
GERD Fivefold higher risk of GERD symptoms in individuals with asthma
Twofold higher risk of asthma in those with GERD
Smoking 15%–35% (current smokers, wide international variations)
22%–43% (ex-smokers)
Device misuse ~70%
Real world inhaled corticosteroid adherence 30%–40%
GERD gastroesophageal reflux disease
(Data from Clatworthy et al. [11], Thomas and Price [12], Giraud and Roche [13], Molimard et al. [14], and Haughney et al. [15])
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response to asthma therapy, the following characteristics are
consistent with an asthma diagnosis: an increase in forced
expiratory volume in 1 s (FEV1)o f≥12% (and 200 mL)
after administration of a bronchodilator (ie, indicative of
reversible airflow limitation), an improvement in peak
expiratory flow (PEF) of 60 L/min (or ≥20% of the
prebronchodilator PEF) after inhalation of a bronchodilator,
or diurnal variation in PEF of more than 20% (with twice-
daily readings, >10%) [3].
The generalizability of criteria used to inform the GINA
therapeutic recommendations was evaluated through a
survey of respiratory health carried out in Wellington,
New Zealand [18]. The New Zealand researchers identified
the eligibility criteria common to all cRCTs published in the
past 30 years that were cited by GINA and were designed
to evaluate asthma drug efficacy in a minimum of 400 adult
patients (n=17 of the 215 cRCTs cited as level A or B
evidence by GINA). Common eligibility criteria in these
trials included a diagnosis of asthma, age older than a lower
age limit, and bronchodilator reversibility. Other inclusion
criteria were a specified FEV1 range, inhaled corticosteroid
(ICS) use, specified symptoms or use of rescue drugs, an
upper age limit age, and peak flow variability. The
proportion of Wellington survey participants with current
asthma and full questionnaire responses and pulmonary
function testing (n=127) who met the eligibility criteria is
summarized in Table 2; only 29% met the GINA-
recommended reversibility diagnostic criterion, and 44%
met the PEF variability criterion [18].
A similar study was conducted in Norway to evaluate the
extent to which a real life obstructive lung disease
population met criteria commonly used in cRCTs [20]. A
minority of patients met the following commonly used
asthma eligibility criteria: FEV1 50% to 85% of predicted
(37.1% eligible), reversibility of 12% within the past year
(14.9% eligible), absence of comorbidity (9.6% eligible),
and nonsmoker (or ex-smoker with a nicotine burden <10
pack-years; 5.4% eligible). If patients were also required to
be symptomatic and to have regular ICS usage, the
percentage of eligible patients fell further to 3.3% (Table 2)
[20]. Thus, in asthma, the typical cRCT population
represents a small minority of patients with asthma treated
in real world everyday clinical practice.
This finding holds true in other areas of respiratory
disease. For example, a recent prospective cohort study
found that of patients treated for allergic rhinitis in
everyday practice, only 7.4% of the 311 patients examined
would have been eligible for major placebo-controlled
RCTs of persistent and intermittent allergic rhinitis [21].
The most common reasons for which the real world patients
with allergic rhinitis would have been excluded from a
cRCT were the absence of an allergy diagnosis based on
skin testing and/or serum-specific IgE testing, insufficient
disease severity, and the presence of comorbidities.
Applicability of Classical Randomized Controlled Trial
Results in Specific Subgroups
Concerns surrounding the limited representative nature of
cRCTs arise where there are data to suggest that cRCT
findings may not hold true in particular subgroups of the
population. Subgroups of particular note within the larger
asthma population include those with poor inhaler tech-
Table 2 Representative nature of cRCTs in asthma: percentage of real world patients with an asthma diagnosis who meet typical cRCT inclusion
criteria
Criterion for inclusion in respiratory cRCT Patients with clinical asthma eligible for cRCTs,%
Travers et al. [18] Herland et al. [20]
Lung function diagnostic criteria outlined
by GINA
Bronchodilator reversibility ≥12% 29 14.9
Peak flow variability ≥20% 44 –
Additional inclusion criteria typically
used in asthma cRCTs
Bronchodilator reversibility ≥15% 24 –
FEV1 ≥50% and <80% of predicted 39 –
FEV1 ≥50% and <85% of predicted – 37.1
Regular inhaled corticosteroid use 52 3.3
Nonsmoker or <10 pack-years of
exposure to cigarette
71 5.4
Active symptoms or use of rescue drugs 80 4.5
FEV1 ≥50% predicted 88 –
No comorbidities – 9.6
cRCT classical randomized controlled trial, FEV1 forced expiratory volume in 1 s, GINA Global Initiative for Asthma
(Adapted from GINA [3], Travers et al. [18], and Herland et al. [20])
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conditions (eg, rhinitis), and those with low adherence to
therapy [11–14, 22–28]. When considering inhaler han-
dling, for example, data suggest a link between poor
technique and poor asthma control, as improper use of
pressurized metered-dose inhalers (pMDIs) for the delivery
of ICS is associated with decreased asthma control [13].
Smoking and severity of rhinitis are also important
determinants of asthma control, as patients with severe
rhinitis and/or higher average cigarette use exhibit poorer
control [11]. Cigarette smoking is known to reduce the
effect of ICS therapy [27–30]. Other factors that have been
shown to affect patients’ response to asthma therapy are
obesity, likely through inflammatory mechanisms [23], and
presence of comorbidities such as COPD and heart failure
[15]. It is often difficult in practice to differentiate between
asthma and COPD, whereas only patients with a clear-cut
diagnosis of asthma are included in cRCTs.
Therefore, the importance of real world factors in
asthma (eg, smoking, comorbidities, patient adherence,
and inhaler technique) should not be overlooked, as they
may explain the wide gap between the level of asthma
control that can be achieved in cRCTs [6]a n dt h e
frequently disappointing results observed in observational
studies carried out among less selected populations [31].
However, data on the comparative effectiveness of
therapies in these subgroups remain lacking. Appropriate-
ly designed studies to address these unanswered research
questions may reveal differential effectiveness of thera-
peutic options in particular patient subgroups and could be
used to help guide more tailored, individualized asthma
management.
Other Gaps in the Evidence Base: Limited Outcome
Evaluation, Duration of Trials, and Ethical Considerations
Another limitation of potential concern resulting from the
high cost of cRCTs is that with few exceptions [4–6], they
tend to be limited in the number of outcomes evaluated and
short in duration, yet the resultant data are used to inform
guidelines for asthma, a chronic disease requiring long-term
management.
Gaps in the evidence base can also arise if ethical
considerations prohibit the completion of a cRCT. The
MASCOT trial, for example, was withdrawn because of
an inability to identify eligible patients [32]. MASCOT
was designed to evaluate the use of combination ICS/
long-acting β2-agonist (LABA) therapy in children of
school age, but most patients who were potentially
eligible were already receiving the study medication.
Altering patients’ routine therapy when it equates to best
standard of care is unethical and can present problems for
trial recruitment.
Plugging the Gaps in the Evidence Base:
Complementary Trial Designs
The need to look beyond asthma cRCTs when faced with
gaps or limitations in the existing evidence base was
recognized in the 2009 European Respiratory Society/
American Thoracic Society Taskforce paper on asthma
control and exacerbations [2]. The Taskforce proposed the
use of composite measures when evaluating asthma
control and called for the measurement properties to be
validated in clinical trials and in “large, prospective
studies in ‘real-world’ settings (eg, trials designed prag-
matically to reflect everyday clinical practice) to ensure
they provide content validity as well as reflect clinically
meaningful outcomes” [2]. Similarly, the Cochrane Col-
laboration, when reviewing the effects of ICS use on linear
growth in children, recognized the need for longer
outcome periods than offered by typical cRCTs and
specifically advised that “research efforts should concen-
trate on evaluating the long-term effects of inhaled
steroids” [33]. The 2008 Brussels Declaration on Asthma
echoed this sentiment by stating in 1 of its 10 key points
that there is a need to “include evidence from real world
studies in treatment guidelines” [34]. The Declaration’s
rationale was that “asthma treatment guidelines are
primarily based on evidence from large clinical trials that
frequently assess lung function as the primary outcome.
However, inflammatory biomarker levels, asthma exacer-
bations, and other outcomes may worsen regardless of
lung function status” [34].
Sir Michael Rawlins [35￿￿], chairman of the United
Kingdom’s National Institute for Health and Clinical
Excellence, added his voice to the debate in 2008 when
he suggested that cRCTs should be complemented by a
diversity of approaches that involve analyzing the totality
of the evidence base. He argued that cRCTs “often miss the
value of a therapeutic intervention and tend to be carried
out in specific types of patients for relatively short periods
of time” [35￿￿]. He contrasted this approach with clinical
practice “where treatments tend to be used on a long-term
basis in a broad variety of patients who often have
comorbid conditions” [35￿￿].
Thus, although cRCTs are the cornerstone of medical
evidence, there are specific areas in which their design
(eg, strict inclusion/exclusion criteria, brevity of duration,
limited outcome evaluation, interventional nature, control
arm requirement) results in gaps in the full evidence
base. Therefore, a role may exist for other study designs,
such as pragmatic trials and observational studies, to
provide data on the effectiveness and comparative
effectiveness of therapies (ie, efficacy as evaluated in
nonidealized patients in more naturalistic, real world
settings).
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Evaluating Real World Effectiveness
The term pragmatic trials was first used in 1967 by
Schwartz and Lellouch [36] to describe trials designed to
help choose between care options. They contrasted this
with explanatory trials that were designed to test causal
research hypotheses (eg, that an intervention causes a
particular biological change). Schwartz and Lellouch [36]
considered there to be a continuum rather than a
dichotomy between explanatory and pragmatic trials, and
characterized pragmatism as an attitude to trial design
rather than a characteristic of the trial itself—an attitude
that has come to be understood as one that maximizes
applicability of trial results to usual care settings, relies on
unequivocally important outcomes (eg, mortality and
s e v e r em o r b i d i t y ) ,a n di st e s t e di naw i d er a n g eo f
participants [37–40].
A trial using this approach for allergic rhinitis found that
guideline-based treatment was more effective than free
treatment choice [41]. Thus, pragmatic clinical trial designs
offer a means of testing a hypothesis in a more naturalistic,
real world setting than cRCTs by modeling and reflecting
everyday clinical practice in their scheduling (eg, longer
treatment exposure) and in their approach to patient
recruitment (eg, including patients with relevant comorbid-
ities). While consenting patients are still assigned randomly
to predefined study arms, pragmatic trials have broader
inclusion criteria [42] than cRCTs and tend to be longer in
duration [43, 44].
The international UPLIFT trial was a pragmatic trial
designed to evaluate the long-term effect of tiotropium
compared with placebo on lung function in patients with
COPD [43]. The UPLIFT design was more naturalistic
than that used in cRCTs, as it allowed patients to continue
taking their standard background therapy (any respiratory
medications except anticholinergic drugs) throughout the
4-year trial. Moreover, UPLIFT used a true intention-to-
treat approach when evaluating the mortality end point;
thus, if patients discontinued study medication during the
trial, they were still included in the final mortality
analysis. It is unfortunate that the other trial end points
were not treated in the same manner [43]. Interestingly,
UPLIFT found the rate of lung function decline in the
“placebo” group (in which two thirds of patients were
receiving an ICS and/or LABA through continuation of
their standard background therapy) to be similar to that
observed in the ICS, LABA, or ICS/LABA groups of the
TORCH study, another long-term trial comparing these
treatments with placebo [45].
Another pragmatic trial of note, commissioned by the
United Kingdom government, is ELEVATE, an equiva-
lence trial evaluating leukotriene receptor antagonists in
primary care at steps 2 and 3 of the national asthma
guidelines [44]. Broad inclusion criteria were defined and
effectiveness outcomes were measured over a 2-year
outcome period; the primary outcome measure was
asthma-related quality of life (QoL), a patient-oriented
measure of effectiveness. Furthermore, the pragmatic trial
design ensured continued patient participation in the study
even if patients did not receive and complete the full
prescribed regimen—a true intention-to-treat approach. As
a result, the dropout rate was only 4% over 2 years in
ELEVATE [44], which compares favorably with cRCT
rates (eg, 25% in GOAL [46]a n d1 6 %i nI M P A C T[ 47]).
Because patients continued to receive care at their usual
practices, ELEVATE achieved high levels of complete data
for the primary end point and high levels of clinical data
from routine practice: more than 90% of patients supplied
data at 2 years for the primary end point, and more than
95% for health care resource and asthma exacerbations.
Previous cRCTs comparing step 2 and 3 asthma therapies
have yielded inconsistent results on the relative efficacy of
the treatment options available [48–54]. In ELEVATE,
leukotriene receptor antagonists were equivalent to the
comparators at 2 months with regard to QoL, and although
equivalence in QoL was not shown at 2 years, there were
no significant differences in secondary measures at either
time point [44].
For seasonal allergic rhinitis, a cluster randomized trial
in primary care showed that patients receiving a treatment
following the international consensus on rhinitis demon-
strated a large improvement compared with those receiving
free treatment choice [55]. In order to be closer to patients’
needs, the primary end point was QoL.
Evaluating Real World Adherence
Pragmatic trials also offer the possibility of evaluating
adherence in a more naturalistic setting than cRCTs. Not
only do cRCTs often demand unrepresentatively high levels
of treatment adherence, but their inherently interventional
nature can also artificially drive adherence.
One approach to more naturalistic adherence data
capture is illustrated by a pragmatic triald e s i g n e dt o
evaluate the impact of dosing regimen on adherence to
asthma medication. Price et al. [56] compared adherence
rates to once-daily and twice-daily mometasone furoate
by capturing adherence data using patient self-report and
dose counters. Patients with poor adherence remained in
the study and thus were included in the final analysis.
Using this approach, a discernible difference in adher-
ence rates was measured between treatment arms, with
greater adherence recorded for the once-daily regimen
[56].
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Evaluating cost-effectiveness of health care interventions is
complicated by the difficulties in placing a monetary value
on improved QoL and reduced morbidity and mortality.
Indeed, drug treatment to prevent morbid events is rarely
cost-saving or cost-neutral, and the ultimate questions that
have to be addressed are as follows:
1. To what extent a patient will benefit from the treatment
and at what cost?
2. How much is the health care system willing to spend to
prevent one morbid event [57]?
Understanding the most appropriate and meaningful data
on which to base cost-effectiveness evaluations can also be
challenging. A study designed to evaluate the external
validity of published cost-effectiveness studies compared
the data used in the published studies (typically based on
cRCTs) with observational data from actual clinical prac-
tice. The authors concluded that cost-effectiveness evalua-
tions based solely on cRCT data lack external validity and,
as they do not represent patients in actual clinical practice,
should not be used to inform prescribing policies [58]. In
light of this, treatment and health technology assessments
should move away from analyses in carefully screened
Remaining Limitations of Pragmatic Trials
Nonetheless, however naturalistic the design of a pragmatic
trial, it still requires patient consent and the involvement of
“trial-minded” physicians. As such, pragmatic trials will
still deal with a defined subgroup of the overall patient and
physician populations, and their protocols still require
closer monitoring of clinical and biological parameters
and more frequent contact with health care professionals
than occurs in standard clinical practice [9, 59–61].
As pragmatic trials are designed to study real world
practice, they are less effective than efficacy trials,
sacrificing internal validity to achieve generalizability
[62]. Poor design and/or execution (true also of some
cRCTs) can bias results toward similar efficacy across
treatment arms and therefore bias the study toward a
finding of equivalence. Better designed pragmatic trials
often include objective outcome measures (eg, survival, test
results) and subjective measures (eg, QoL surveys), which,
if broadly consistent, can diminish concerns about potential
bias [62].
Additional challenges arise from the fact that the very
characteristics of real world practice that pragmatic trials
are designed to capture—including variable adherence, use
of concomitant therapies, presence of comorbidities,
changeable symptoms over time—tend to reduce measure-
able differences between therapies. Such concerns highlight
the benefit of including both an intention-to-treat and a per-
protocol analysis to allow regression to equivalence [63,
64]. Some of these shortcomings can be addressed—to
varying degrees—by observational studies.
The Role of Observational Studies
Their Contribution
As defined by the National Centre for Biotechnology
Information, an observational study is a “type of non-
randomized study in which the investigators do not seek to
intervene, instead simply observing the course of events”
[65]. As such, observational studies using clinical databases
offer another method of studying the comparative effec-
tiveness of outcomes as evaluated in real world patients in a
noninterventional, naturalistic setting. They also provide a
means to study, characterize, and better understand real
world prescribing practices and adherence to guidelines in
clinical practice. Observational studies involve accessing,
collating, and analyzing information held in patient records
and can be cross-sectional or longitudinal in design [9].
Although they are limited by the lack of treatment
randomization and potential bias through subjectivity of
treatment choice, their use of routine clinical data gives
them high external validity.
Prospective cohort studies provide important informa-
tion, but they can be expensive to conduct and take many
years to generate results; moreover, for logistical reasons,
only a relatively small number of patients can be observed.
This limits their power to detect differences in outcomes
between subgroups, especially when considering relatively
rare outcomes (eg, exacerbations, death). Conversely,
retrospective studies look at events in the past (as recorded
in patients’ clinical records), allowing the generation of
more immediate results. Retrospective studies are also less
restricted by patient numbers than prospective studies, as
cohort definition can ensure sufficient numbers to demon-
strate differences in treatment response (where such differ-
ences really exist). Well-designed database studies, while
inherently retrospective, define patient cohorts and out-
comes a priori based on a prespecified index event, such as
a recorded treatment change (see later study examples),
which can result in useful hypothesis testing. This contrasts
with more skeptical views of databases being used
inversely to suggest rather than answer questions.
The General Practice Research Database and the Doctors
Independent Network (DIN-Link) Database in the United
Kingdom are clinical databases that have been extensively
used for research [66–69]. They comprise patient records
collected over years, not months, thereby allowing inves-
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populations toward actual cost-effectiveness trials using real
world clinical data [57].tigation of longitudinal treatment effects. These features are
invaluable in hypothesis generation and testing and can also
help refine the design and powering of RCTs [9].
Evaluating Guideline Implementation
Observational studies can help evaluate guideline imple-
mentation in everyday clinical practice. In the United
States, an observational study was carried out using an
integrated managed care database to characterize the
patterns of care observed in patients prior to emergency
department (ED) treatment of acute asthma [70]. The study
was motivated by the limited data on resource use prior to
ED attendance and the recognition that better understanding
of treatment patterns prior to an ED visit may help identify
opportunities for improved interventions. The study ex-
plored adherence to guideline recommendations through
evaluation of ICS therapy in the year prior to the ED visit
and through quantification of short-acting β2-agonists and
oral corticosteroids and rescue medications in the year
before and in the month after the ED visit. Also
investigated was the impact of the acute care intervention
in the ED on altering the prescription of ICS and other
asthma medications in the 2 months after the ED event. The
study demonstrated a high dependence on rescue medica-
tions—short-acting β2-agonists and oral corticosteroids—in
this population prior to ED attendance, and that the ED
event resulted in only an incremental short-term improve-
ment in ICS-containing controller treatment. Such charac-
Table 3 Summary of demographic and clinically important matching
criteria used by Price et al. [77] and Barnes et al. [78] to ensure
baseline similarity of patients in the different treatment arms
Matching criterion Categories
Oral corticosteroid prescriptions during baseline year 0, 1, 2, 3, ≥4
Sex Male/female
Mean SABA dose during the baseline year, μg/d 0
1–100
101–200
201–300
301–400
≥400
Age ≥13±5 y or
6–12±3 y or
5±1 y
For step-up population only: mean ICS dose
prescribed during the baseline year, μg/d
0–99
100–199
200–299
300–399
400–599
600–799
≥800
For EF HFA-BDP vs CFC-BDP analysis only:
number of asthma consultations without resulting
in a prescription for oral corticosteroids
0, 1, 2, 3
CFC-BDP chlorofluorocarbon beclomethasone dipropionate, EF HFA-
BDP extra-fine hydrofluoroalkane beclomethasone dipropionate, ICS
inhaled corticosteroid, SABA short-acting β2-agonist
Table 4 Summary of co–primary outcomes: OR for achieving asthma control and rate ratio of exacerbations
a
CFC-BDP as the reference group (OR, 1.00) QVAR vs BDP
Initiation population Step-up population
EF HFA-BDP (N=2,882) EF HFA-BDP (N=258)
Primary measure of asthma control, adjusted OR (95% CI) 1.15 (1.02–1.28)
b 1.72 (1.14–2.56)
c
Exacerbation during the outcome year, adjusted rate ratio (95% CI) 0.95 (0.81–1.12)
d 0.64 (0.39–1.05)
e
FP as the reference group (OR, 1.00) QVAR vs FP
Initiation population Step-up population
EF HFA-BDP (N=1,319) EF HFA-BDP (N=250)
Primary measure of asthma control, adjusted OR (95% CI) 1.30 (1.02–1.65)
f 1.22 (0.66–2.26)
g
Exacerbation during the outcome year, adjusted rate ratio (95% CI) 0.96 (0.85–1.08)
f 1.08 (0.82-1.43)
g
a From Price et al. [77] and Barnes et al. [78] 2-way matched analyses of EF HFA-BDP vs FP, and EF HFA-BDP vs CFC-BDP, respectively;
outcomes for the matched treatment arms were adjusted for residual baseline differences
bAdjusted for age and baseline paracetamol prescriptions, antibiotics, and number of non–asthma-related consultations
cAdjusted for number of non–asthma-related consultations
dAdjusted for age and baseline antibiotics and number of non–asthma-related consultations.
eNo significant effects (unadjusted OR)
fAdjusted for year of index date, acetaminophen, asthma consultations, rhinitis diagnosis, recorded asthma diagnosis, and cardiac disease diagnosis
gAdjusted for year of index date, acetaminophen, asthma consultations, and rhinitis diagnosis
CFC-BDP chlorofluorocarbon beclomethasone dipropionate, EF HFA-BDP extra-fine hydrofluoroalkane beclomethasone dipropionate, FP
fluticasone propionate
532 Curr Allergy Asthma Rep (2011) 11:526–538terization of prescribing patterns in real world clinical
practice requires observational, noninterventional methods
and cannot be achieved through cRCTs [14].
Evaluating Real World Influence of Inhaler Device Type
Another area of asthma management in which study
alternatives to cRCTs can provide useful information is
in the evaluation of inhaler type. Asthma cRCTs typically
train recruited patients in inhaler technique and often
require trial participants to be able to demonstrate and
maintain proper inhalation technique throughout. How-
ever, in real world practice, many patients use their
inhaler devices incorrectly, and proper inhaler technique
is infrequently reinforced [14, 71, 72].
The REALITY study used the General Practice
Research Database to evaluate the comparative effective-
ness of different inhaler types as used in everyday
asthma management [73–75]. Participating patients com-
menced or increased ICS therapy via a range of different
inhaler types (pMDIs, breath-actuated metered-dose
inhalers [BAIs], and dry powder inhalers). No require-
ments were placed on patients’ inhaler training beyond
routine standard care. Significant differences in the odds
of achieving successful asthma control were found for
both BAI- and dry powder inhaler–treated patients
compared with patients using pMDIs [74]. Moreover,
these differences had significant health economic implica-
tions, with BAIs being on average more cost-effective
than pMDIs [73].
Evaluating Real World Effectiveness
Although well-designed observational studies have good
external validity, they lack the internal validity of cRCTs.
One of the main challenges of observational studies is
ensuring adequate treatment group comparability, but
expertise is growing and methodologies are continually
evolving that assess baseline comparability of the study
cohorts and also validate outcomes for consistency across
multiple subgroups [76]. When study cohorts are similar at
baseline, outcome analysis can proceed with suitable
statistical adjustments being made for any characteristics
that are statistically or clinically significantly different
between cohorts or are strongly predictive of the outcome
[77, 78]. Where cross-sectional baseline data reveal
substantial differences between groups, a matched cohort
analysis (or other suitable methodology, such as propensity-
based matching) should be used. Patients are matched on
key demographic and clinical baseline characteristics to
minimize any differences in baseline disease severity and to
ensure that strongly confounding baseline effects are
comparable across treatment groups, thus allowing study
outcomes to be appropriately interpreted [79].
In this regard, Price et al. [77, 78] employed a matched
cohort approach to an effectiveness and cost-effectiveness
Table 5 Distribution of prescribed doses at the index date in the Price et al. [77] and Barnes et al. [78] 2-way matched analyses of EF HFA-BDP
vs FP, and EF HFA-BDP vs CFC-BDP
a
Initiation population Step-up population
QVAR vs BDP
b (Fig. 1b) EF HFA-BDP (N=2,882) CFC-BDP (N=2,882) EF HFA-BDP (N=258) FP (N=258)
Distribution of patients by
mean ICS dose prescribed
at the index date,%
1–199 μg/d 30 1.1 2.3 0.0
200–399 μg/d 60.3 12.9 39.1 2.5
400–799 μg/d 19.0 69.0 65.4 33.5
800–1,199 μg/d 1.0 16.0 3.1 57.8
≥1,200 μg/d 0.0 1.1 0.0 6.2
QVAR vs FP (Fig. 1b) EF HFA-BDP (N=1,319) FP (N=1,319) EF HFA-BDP (N=250) FP (N=250)
Distribution of patients by
mean ICS dose prescribed
at the index date,%
0–99 μg/d 0.0 5.5 0.0 0.0
100–199 μg/d 29.8 18.7 1.6 1.6
200–299 μg/d 50.2 35.9 32.1 24.3
300–399 μg/d 0.3 0.3 0.5 0.7
400–599 μg/d 18.9 28.4 59.3 42.9
600–799 μg/d 0.2 0.1 1.1 0.7
≥800 μg/d 0.7 10.9 5.2 29.7
aPrescribed doses were significantly lower for both the initiation and step-up EF HFA-BDP populations across both studies (P<0.001)
bDaily ICS dose during the outcome year was calculated as the dispensed amount divided by 365 (the licensed dose of EF HFA-BDP dose is
~50% that of CFC-BDP)
BDP beclomethasone dipropionate, CFC-BDP chlorofluorocarbon beclomethasone dipropionate, EF HFA-BDP extra-fine hydrofluoroalkane
beclomethasone dipropionate, FP fluticasone propionate, ICS inhaled corticosteroid
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dipropionate (EF HFA-BDP; QVAR [Teva Respiratory,
Horsham, PA]) pMDI, fluticasone propionate (FP) pMDI,
and chlorofluorocarbon-BDP pMDI therapies. To ensure
similarity of asthma severity at baseline, patients in the EF
HFA-BDP and FP [77], and in the EF HFA-BDP and BDP
[78] groups were matched on important demographic and
asthma-related baseline characteristics prior to outcome
evaluation (Table 3). The two separate matched cohort
analyses found that in a real world setting, patients receiving
EF HFA-BDP had a similar or better chance of achieving
asthma control at lower prescribed doses than with FP [77]
or chlorofluorocarbon-BDP (Table 4, Table 5,a n dF i g .1)
[78]. These findings were reinforced by similar outcomes in
the unmatched cohort analyses and the consistency of
subanalysis results for age group and smoking status.
Remaining Limitations of Observational Studies
In addition to the difficulties in achieving comparability of
treatment arms, another past criticism of observational
studies has been their purported tendency to overestimate
treatment effects [79]. More recent reviews suggest that
such concerns are largely unfounded. A pooled analysis of
observational studies and cRCTs (taken from the Medline,
Abridged Index Medicus, and Cochrane databases between
Fig. 1 a and b Illustration of the distribution of prescribed doses at the
index date in Barnes et al. [78] and two-way matched analyses of extra-
fine hydrofluoroalkane beclomethasone dipropionate (EF HFA-BDP)
versus chlorofluorocarbon beclomethasone dipropionate (CFC-BDP).
(Reprinted from J Clin Exp Allergy, 14 July 2011, Barnes N, Price D,
Colice G, et al.: Asthma control with extrafine-particle hydrofluoroal-
kane–beclometasone vs. large-particle chlorofluorocarbon–beclometa-
sone: a real-world observational study, doi: 10.1111/j.1365-
2222.2011.03820.x. [Epub ahead of print], copyright 2011, with
permission from John Wiley and Sons.) c and d Illustration of the
distribution in Price et al. [77] two-way matched analysis of EF HFA-
BDP versus fluticasone propionate (FP). Prescribed doses were
significantly different between treatment cohorts in both the initiation
and step-up populations for both the EF HFA-BDP versus CFC-BDP
and the EF HFA-BDP versus FP matched analyses (P<0.001).
(Reprinted from J Allergy Clin Immunol vol. 126, Price D, Martin RJ,
Barnes N, et al.: Prescribing practices and asthma control with
hydrofluoroalkane-beclomethasone and fluticasone: a real-world obser-
vational study, pages 511–518 e511-510, copyright 2010, with permis-
sion from Elsevier.) Prescribed doses were significantly different
between treatment cohorts in both the initiation and step-up populations
for both the EF HFA-BDP versus CFC-BDP and the EF HFA-BDP
versus FP matched analyses (P<0.001)
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interventions for the same condition were evaluated, found
little evidence to suggest that treatment effects reported in
the observational studies were consistently larger than or
qualitatively different from those reported in the cRCTs.
The analysis involved 136 reports across 19 diverse
treatments. In only 2 of the 19 analyses of treatment effects
did the combined magnitude of the effect in the observa-
tional studies lie outside the 95% CI for the combined
magnitude reported in the cRCTs [80].
The knowledge of how to work with clinical databases and
quality of practice-based patient data is continually improving
as researchers collaborate and work with contributing practi-
ces to ensure thatrelevant, high-qualitydataare recorded. The
matched cohort approach and validation of outcomes across
subgroups that has emerged in recent observational research
shouldhelpmitigateconcernsaroundconfoundingoffindings
through differences in study populations. However, their real
strength will continue to lie in hypothesis generation and
testing, helping to identify areas in which further rigorous
clinical trials are required.
To increase confidence in the results of databaseanalyses,it
is of the utmost importance to describe (ap r i o r i ) in a detailed
study protocol all planned analyses before they begin, exactly
as for a cRCT. In that respect, the move toward greater ethical
transparency in medical research, which requires increasing
numbers of publicly and privately funded clinical trials to be
registered and published in online study databases and
centralized repositories (eg, http://www.clinicaltrials.gov),
should also help improve communication of quality method-
ologies and gradually drive out poorly designed studies that
can undermine the field of observational research.
The reporting of observational studies should follow the
STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) guidelines [81], while reporting
of real life trials should follow the CONSORT (Consoli-
dating Standards of Reporting Trials) guidelines for cluster
randomized trials [82] and pragmatic trials [40].
Conclusions
Data from cRCTs represent the gold standard for evaluating
treatment safety and efficacy, owing to rigorous trial design
and strong internal validity. However, no study design is
without its limitations, and questions exist concerning the
generalizabilityofcRCTfindingstothewidelyheterogeneous
asthma population, and their accuracy over the longer term.
Observational studies have high external validity and may
assist inanswering some of the questions that cRCTs have not
yet answered or cannot answer. Contrastingly, their internal
validity is often poor, but it can be improved by detailed a
priori analysis planning and by grounding database analyses
on rational hypotheses. Pragmatic clinical trials with appro-
priate quality checks are positioned between the two. As
recently proposed by ARIA (Allergic Rhinitis and its Impact
on Asthma) and GA
2LEN (Global Allergy and Asthma
European Network), a combination of all these approaches is
probably needed because all have advantages and drawbacks
and do not answer the same question [83].
The evidence base in asthma and respiratory medicine
must be reviewed openly and broadly, and while cRCTs
unequivocally lie at the core, quality contributions from
well-designed pragmatic trials and observational studies also
should be recognized and considered for the complementary
role that they play.
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